Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.285 USD | +29.10% | +20.14% | -3.89% |
Apr. 24 | Tilray Brands, Inc. Introduces New Signature 'Bud Squad' Products | CI |
Apr. 23 | TSX climbs as tech stocks power broader recovery | RE |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 52% by 2026.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company has insufficient levels of profitability.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.89% | 1.37B | C- | ||
+33.34% | 664B | C+ | ||
+29.29% | 567B | B | ||
-7.14% | 354B | C+ | ||
+19.12% | 330B | B- | ||
+4.74% | 286B | C+ | ||
+13.79% | 234B | B+ | ||
+4.93% | 199B | B- | ||
-9.78% | 196B | A+ | ||
-4.69% | 148B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- TLRY Stock
- Ratings Tilray Brands, Inc.